FFR Driven Complete Revascularization Versus Usual Care in NSTEMI Patients and Multivessel Disease

Inclusion Criteria:

• Patients aged between 18-85 years presenting with non-STEMI according to currentguidelines, who will be treated with PCI of the culprit and have at least onestenosis of >50% in a non-IRA on QCA or visual estimation of baseline angiographyand judged feasible for treatment with PCI by the operator.

• Non-IRA stenosis amenable for PCI treatment (operator's decision)

• Signed informed consent

Exclusion Criteria:

• Left main disease (stenosis > 50%)

• Chronic total occlusion of a non-IRA

• Indication for or previous coronary artery bypass grafting

• Uncertain culprit lesion

• Complicated IRA treatment, e.g. extravasation, permanent no re-flow after IRAtreatment (TIMI flow 0-1) and inability to implant a stent

• Known severe cardiac valve dysfunction that will require surgery or TAVI in thefollow-up period.

• Killip class III or IV during the completion of culprit lesion treatment.

• Life expectancy of < 1 year.

• Intolerance to Aspirin, Clopidogrel, Prasugrel, Ticagrelor or Heparin.

• Gastrointestinal or genitourinary bleeding within the prior 3 months.

• Planned elective surgical procedure necessitating interruption of thienopyridinesduring the first 6 months post enrolment.

• Patients who are actively participating in another drug or device investigationalstudy, which have not completed the primary endpoint follow-up period.

• Pregnancy